InvestSMART

Acrux Limited (ASX: ACR) - Announcements

- Current share price for ACR : $0.011

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Change in substantial holding 4 Nov 2016 4:28PM $0.325 $0.011 fallen by 96.62%
$7 IPR Petition Filed Against Key Jublia Patent 3 Nov 2016 9:47AM $0.335 $0.011 fallen by 96.72%
$7 NEW INTELLECTUAL PROPERTY APPLICATION FOR ONYCHOMYCOSIS 2 Nov 2016 10:32AM $0.335 $0.011 fallen by 96.72%
$7 Axiron Net Sales, Quarter to September 2016 26 Oct 2016 8:51AM $0.335 $0.011 fallen by 96.72%
$7 Change in Company Secretary 10 Oct 2016 1:49PM $0.340 $0.011 fallen by 96.76%
$7 Acrux 2016 Annual Report 7 Oct 2016 8:29AM $0.335 $0.011 fallen by 96.72%
$7 Notice of 2016 Annual General Meeting and Proxy Form 7 Oct 2016 8:29AM $0.335 $0.011 fallen by 96.72%
$7 Change of Melbourne Registry Address Notification 9 Sep 2016 4:31PM $0.370 $0.011 fallen by 97.03%
$7 Change in substantial holding 30 Aug 2016 5:58PM $0.345 $0.011 fallen by 96.81%
$7 Change in substantial holding 25 Aug 2016 4:43PM $0.420 $0.011 fallen by 97.38%
$7 Acrux Financial Report for the year ended 30 June 2016 25 Aug 2016 9:32AM $0.440 $0.011 fallen by 97.50%
$7 Acrux announces 2016 financial results 25 Aug 2016 9:24AM $0.440 $0.011 fallen by 97.50%
$7 Appendix 4G 25 Aug 2016 9:23AM $0.440 $0.011 fallen by 97.50%
$7 Appendix 4E 25 Aug 2016 9:22AM $0.440 $0.011 fallen by 97.50%
$7 Acrux and Eli Lilly to appeal patent ruling on Axiron 24 Aug 2016 10:16AM $0.405 $0.011 fallen by 97.28%
$7 Acrux announces court ruling on Axiron patent families 23 Aug 2016 11:59AM $0.705 $0.011 fallen by 98.44%
$7 2016 Annual Results and Investor Conference Call 22 Aug 2016 12:22AM $0.703 $0.011 fallen by 98.43%
$7 Acrux defers release of 2016 financial results 8 Aug 2016 2:20PM $0.770 $0.011 fallen by 98.57%
$7 2016 Annual Results - investor conference call 4 Aug 2016 4:23PM $0.760 $0.011 fallen by 98.55%
$7 Axiron Net Sales, quarter to June 2016 27 Jul 2016 8:55AM $0.830 $0.011 fallen by 98.67%
$7 Acrux generic strategy and Axiron patent litigation update 30 Jun 2016 9:53AM $0.710 $0.011 fallen by 98.45%
$7 Appendix 3Y 10 Jun 2016 6:39PM $0.780 $0.011 fallen by 98.59%
$7 Acrux announces non-executive board appointments 1 Jun 2016 9:15AM $0.720 $0.011 fallen by 98.47%
$7 Acrux presents at BioTrinity 27 Apr 2016 9:08AM $0.640 $0.011 fallen by 98.28%
$7 Axiron Net Sales, quarter to March 2016 27 Apr 2016 9:06AM $0.640 $0.011 fallen by 98.28%

476 - 500 of 706 results

Page 20 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.